Shaanxi Micot Pharmaceutical Technology
2335 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Shaanxi Micot Pharmaceutical Technology are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CaSR; OGPPeptide | Chronic Kidney Disease Secondary Hyperparathyroidism |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $0 | $5.5M | — | $6.9M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $15M | — | $22M | report ↗ |
In the 2024 fiscal year, the company reported revenue of $0M (prior year $0M), with no operating revenue generated. R&D spend was $14.89M, up 21.0% YoY from $12.31M. Cash and equivalents were not disclosed, and net income/loss was not disclosed; the quarterly net burn was $21.85M.
The company filed a Hong Kong IPO prospectus in late September 2025, with CCB International and China Merchants Securities International as joint sponsors. Its lead candidate MT1013, a dual-target receptor agonist for secondary hyperparathyroidism, completed a Phase II trial and entered Phase III. Other key pipeline assets include XTL6001, a triple-target agonist in Phase I for weight management, and MT1002 and MT200605, both of which have completed Phase I and are advancing to Phase II studies.
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | $0 | $12M | — | $28M | report ↗ |